$ARDX @ArdelyxMedical @ardelyx Honest Question to CEO Raab: Given CMS’s 2025 final rule extending the implementation of the new three-year TDAPA eligibility limitation until January 1, 2028, has Ardelyx reevaluated its July 2024 decision not to seek TDAPA for XPHOZAH, and has management or the Board analyzed the potential economic benefit of filing an application before the January 1, 2028 deadline, including the financial impact of XPHOZAH supplied through Ardelyx’s patient assistance program? That is a much harder question for you to dismiss, because it points directly to a specific regulatory change and asks whether the company has actually reconsidered its previous decision. You have a fiduciary duty as does your board to answer this. I’ve run the numbers and you might be shocked
在 X 查看 ↗